Lourd Capital LLC Acquires Shares of 1,571 Allergan plc (AGN)

Lourd Capital LLC acquired a new position in shares of Allergan plc (NYSE:AGN) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 1,571 shares of the company’s stock, valued at approximately $299,000.

Other hedge funds have also recently bought and sold shares of the company. Flagship Harbor Advisors LLC bought a new position in shares of Allergan in the second quarter worth $129,000. Kaizen Advisory LLC increased its position in shares of Allergan by 156.2% in the second quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock worth $138,000 after purchasing an additional 506 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Allergan by 3,193.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock worth $165,000 after purchasing an additional 958 shares during the period. Aries Wealth Management bought a new position in shares of Allergan in the second quarter worth $202,000. Finally, NEXT Financial Group Inc bought a new position in shares of Allergan in the third quarter worth $222,000. Hedge funds and other institutional investors own 77.38% of the company’s stock.

In other news, Director Joseph H. Boccuzi purchased 900 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction dated Thursday, September 6th. The shares were purchased at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. Company insiders own 0.37% of the company’s stock.

Several analysts recently weighed in on AGN shares. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. ValuEngine raised Allergan from a “strong sell” rating to a “sell” rating in a research note on Friday, September 21st. TheStreet raised Allergan from a “d+” rating to a “c” rating in a research note on Monday, August 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $180.00 price objective on shares of Allergan in a research note on Friday, September 14th. Finally, Wells Fargo & Co set a $232.00 price objective on Allergan and gave the company a “buy” rating in a research note on Wednesday, August 22nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company. Allergan presently has a consensus rating of “Buy” and a consensus price target of $211.91.

Shares of AGN stock opened at $183.28 on Friday. Allergan plc has a 12 month low of $142.81 and a 12 month high of $207.24. The stock has a market cap of $64.66 billion, a PE ratio of 11.21, a PEG ratio of 1.47 and a beta of 1.19. The company has a current ratio of 1.00, a quick ratio of 0.85 and a debt-to-equity ratio of 0.34.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Thursday, July 26th. The company reported $4.42 EPS for the quarter, beating the Zacks’ consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the firm posted $4.02 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Equities analysts predict that Allergan plc will post 16.29 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, September 17th. Stockholders of record on Friday, August 17th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.57%. The ex-dividend date of this dividend was Thursday, August 16th. Allergan’s payout ratio is 17.61%.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Featured Article: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply